INTRATHECAL BACLOFEN FOR SEVERE SPASTICITY
INTRATHECAL BACLOFEN FOR SEVERE SPASTICITY
复制标题
DOI:
10.1111/j.1749-6632.1988.tb31822.x
复制
发表时间:
1988-06-01
影响因子:
5.2
通讯作者:
PENN, RD
中科院分区:
文献类型:
--
作者:
PENN, RD
Over the past three years, we have taken a new approach to the control of spasticity. It is based on the clinical observation that oral baclofen reduces spasticity in patients with complete anatomical transection of the spinal cord. This means that baclofen can have its clinical effect by acting solely upon spinal circuitry. The difficulty in achieving a good therapeutic response is that oral baclofen is distributed equally to the brain and spinal cord, so that increases in systemic drug concentration result in drowsiness and mental confusion along with control of spasticity. The solution is to change the distribution of drug by preferentially perfusing the spinal cord. To accomplish this, an implanted drug pump is connected to a catheter and baclofen is slowly injected into the lumbar cerebrospinal fluid (CSF). The results of this modification in drug delivery are dramatic.’Patients whose spasticity had been so severe that surgical procedures to cut nerve roots had been considered have had their muscle tone reduced to normal and spasms reduced so they no longer cause symptoms. The daily dose of baclofen can be reduced one hundredfold and central side effects do not occur. In this paper I will first present the results of our clinical studies on sixteen patients on chronic intrathecal baclofen and then discuss the reasons why the technique seems to work so well, and what lessons can be drawn for other neurological applications of drug pumps.